Работы, цитирующие эту работу

Работ: 2

Работа: A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

1. Development of criteria for the selection of therapeutic effects on metastatic renal cell carcinoma considering the factors of tumor microenvironment.

   M.N. Tillyashaykhov, Tashkent, Uzbekistan, E.V. Boyko +3

   СтатьяRenal cell carcinoma treatmentExperimental and Сlinical Urology2023Цитирований: 0

   ABIABI:AkademIndex/openalex/2023.article.006571

2. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

   Saade Abdalkareem Jasim, I.M. Farber, Sara Abdalrazzaq M. Noraldeen +7

   СтатьяAngiogenesis and VEGF in CancerMicrovascular Research2024Цитирований: 0

   ABIABI:AkademIndex/openalex/2024.article.003439